{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:27:09Z","timestamp":1777865229351,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004955","name":"\u00d6sterreichische Forschungsf\u00f6rderungsgesellschaft","doi-asserted-by":"publisher","award":["858017"],"award-info":[{"award-number":["858017"]}],"id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejmech.2019.111748","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T11:19:53Z","timestamp":1570101593000},"page":"111748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators"],"prefix":"10.1016","volume":"185","author":[{"given":"Anna M.","family":"Schoepf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2391-6954","authenticated-orcid":false,"given":"Stefan","family":"Salcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Obexer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Gust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.111748_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.111748_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in\u00a0vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2019.111748_bib3","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2019.111748_bib4","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2019.111748_bib5","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2019.111748_bib6","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Saussele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2019.111748_bib7","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2019.111748_bib8","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2019.111748_bib9","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.111748_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccell.2015.09.017","article-title":"PPARgamma: welcoming the new kid on the CML stem cell block","volume":"28","author":"Apsel Winger","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2019.111748_bib11","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.3390\/ijms19113540","article-title":"Peroxisome proliferator-activated receptors (PPAR)gamma agonists as master modulators of tumor tissue","volume":"19","author":"Heudobler","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2019.111748_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/cbdd.12737","article-title":"Peroxisome proliferator-activated receptor ligands and their role in chronic myeloid leukemia: therapeutic strategies","volume":"88","author":"Yousefi","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2019.111748_bib13","doi-asserted-by":"crossref","first-page":"816856","DOI":"10.1155\/2015\/816856","article-title":"Review of the structural and dynamic mechanisms of PPAR\u03b3 partial agonism","volume":"2015","author":"Kroker","year":"2015","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejmech.2019.111748_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2018.01.036","article-title":"PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy","volume":"823","author":"To","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111748_bib15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2018.01.020","article-title":"Anti-leukemic effects of PPAR\u03b3 ligands","volume":"418","author":"Ryu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2019.111748_bib16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/2211-5463.12055","article-title":"Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells","volume":"6","author":"Kozako","year":"2016","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ejmech.2019.111748_bib17","doi-asserted-by":"crossref","first-page":"32696","DOI":"10.1155\/2007\/32696","article-title":"Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects","volume":"2007","author":"Zhang","year":"2007","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejmech.2019.111748_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/cmdc.200800285","article-title":"Characterization of new PPAR\u03b3 agonists: analysis of telmisartan\u2019s structural components","volume":"4","author":"Goebel","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111748_bib19","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/cmdc.200900067","article-title":"Characterization of new PPARgamma agonists: benzimidazole derivatives - the importance of position 2","volume":"4","author":"Goebel","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111748_bib20","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0022-2275(20)32433-0","article-title":"Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation","volume":"40","author":"Raspe","year":"1999","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2019.111748_bib21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-07-0397","article-title":"Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells","volume":"7","author":"Hui","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2019.111748_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejmech.2016.08.027","article-title":"New telmisartan-derived PPAR\u03b3 agonists: impact of the 3D-binding mode on the pharmacological profile","volume":"124","author":"Obermoser","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111748_bib23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ejmech.2016.11.051","article-title":"Importance of 5\/6-aryl substitution on the pharmacological profile of 4\u02b9-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1\u02b9-biphenyl]-2-carboxylic acid derived PPAR\u03b3 agonists","volume":"126","author":"Obermoser","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111748_bib24","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1007\/s00044-014-1068-z","article-title":"Quinoxaline-2,3-diones: potential d-amino acid oxidase (DAAO) inhibitors","volume":"23","author":"Xie","year":"2014","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2019.111748_bib25","first-page":"1","volume":"2008","author":"Chen","year":"2008"},{"key":"10.1016\/j.ejmech.2019.111748_bib26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/jctb.5010020409","article-title":"The preparation of 1-chloro-2,6-dinitrobenzene","volume":"2","author":"Gunstone","year":"1952","journal-title":"J.\u00a0Appl. Chem."},{"key":"10.1016\/j.ejmech.2019.111748_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/cmdc.201000450","article-title":"Design, synthesis and biological evaluation of novel inhibitors of trypanosoma brucei pteridine reductase 1","volume":"6","author":"Spinks","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111748_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/00304949909458332","article-title":"Simple, high yield preparation of 3-nitro-1,2-phenylenediamine","volume":"31","author":"Milata","year":"1999","journal-title":"Org. Prep. Proced. Int."},{"key":"10.1016\/j.ejmech.2019.111748_bib29","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1021\/jo01364a008","article-title":"Sandmeyer reactions of monoacyl arylenediamines","volume":"20","author":"Bergmann","year":"1955","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2019.111748_bib30","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1039\/c2dt12373h","article-title":"Investigating chelating sulfonamides and their use in metalloproteinase inhibitors","volume":"41","author":"Tanakit","year":"2012","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2019.111748_bib31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1081\/SCC-200051681","article-title":"Fe-HCl: an efficient reagent for deprotection of oximes as well as selective oxidative hydrolysis of nitroalkenes and nitroalkanes to ketones","volume":"35","author":"Pradhan","year":"2005","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2019.111748_bib32","series-title":"Comprehensive organic functional group transformations","author":"Katritzky","year":"1995"},{"key":"10.1016\/j.ejmech.2019.111748_bib33","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.1002\/ejoc.201501042","article-title":"Ether cleavage re-investigated: elucidating the mechanism of BBr3-facilitated demethylation of aryl methyl ethers","volume":"2015","author":"Kosak","year":"2015","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2019.111748_bib34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/cb3006243","article-title":"Nonsteroidal bivalent estrogen ligands: an application of the bivalent concept to the estrogen receptor","volume":"8","author":"Shan","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.111748_bib35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0022-4731(75)90042-4","article-title":"Screening for anti-hormones by receptor studies","volume":"6","author":"Raynaud","year":"1975","journal-title":"J.\u00a0Steroid Biochem."},{"key":"10.1016\/j.ejmech.2019.111748_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ejmech.2019.111748_bib37","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.exphem.2012.05.013","article-title":"Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells","volume":"40","author":"Wang","year":"2012","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmech.2019.111748_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12943-017-0661-4","article-title":"C10ORF10\/DEPP-mediated ROS accumulation is a critical modulator of FOXO3-induced autophagy","volume":"16","author":"Salcher","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2019.111748_bib39","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/cmdc.201600417","article-title":"Targeting a targeted drug: an approach toward hypoxia-activatable tyrosine kinase inhibitor prodrugs","volume":"11","author":"Karnthaler-Benbakka","year":"2016","journal-title":"ChemMedChem"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419309006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419309006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:59:05Z","timestamp":1777528745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419309006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":39,"alternative-id":["S0223523419309006"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111748","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111748"}}